Table 3.
Univariate and multivariate analysis of overall survival (OS) and breast cancer-specific survival (BCSS) of the study population.
| Univariate analysis | Multivariate analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| OS | BCSS | OS | BCSS | ||||||
| HRs (95% CI)a | P-value | HRs (95% CI) | P-value | HRs (95% CI) | P-value | HRs (95% CI) | P-value | ||
| Age | <50 years | 0.72 (0.64–0.82) | P < 0.001 | 0.78 (0.68–0.88) | P < 0.001 | 0.77 (0.68–0.87) | P < 0.001 | 0.81 (0.71–0.92) | 0.002 |
| 50–69 years | reference | — | reference | — | reference | — | reference | — | |
| >69 years | 1.50 (1.38–1.64) | P < 0.001 | 1.43 (1.30–1.57) | P < 0.001 | 1.56 (1.43–1.70) | P < 0.001 | 1.52 (1.38–1.68) | P < 0.001 | |
| Gender | Female | reference | — | reference | — | reference | — | reference | — |
| Male | 1.04 (0.71–1.51) | 0.850 | 1.03 (0.68–1.55) | 0.907 | 0.96 (0.66–1.40) | 0.962 | 0.99 (0.65–1.50) | 0.954 | |
| Year of diagnosis | 2010 | reference | — | reference | — | reference | — | reference | — |
| 2011 | 0.93 (0.84–1.03) | 0.175 | 0.91 (0.82–1.02) | 0.913 | 0.94 (0.85–1.04) | 0.214 | 0.91 (0.82–1.02) | 0.111 | |
| 2012 | 0.97 (0.86–1.08) | 0.532 | 0.96 (0.85–1.02) | 0.481 | 0.98 (0.88–1.10) | 0.714 | 0.97 (0.86–1.10) | 0.605 | |
| 2013 | 0.94 (0.82–1.08) | 0.402 | 0.94 (0.81–1.10) | 0.440 | 0.92 (0.80–1.06) | 0.230 | 0.91 (0.78–1.06) | 0.241 | |
| Race | White | reference | — | reference | — | reference | — | reference | — |
| Black | 1.20 (1.09–1.33) | P < 0.001 | 1.17 (1.05–1.31) | 0.006 | 1.22 (1.10–1.36) | P < 0.001 | 1.15 (1.03–1.29) | 0.015 | |
| Others | 0.83 (0.70–0.98) | 0.023 | 0.87 (0.73–1.04) | 0.116 | 0.91 (0.77–1.08) | 0.270 | 0.93 (0.78–1.11) | 0.419 | |
| Unknown | 0.35 (0.13–0.95) | 0.038 | 0.43 (0.16–1.13) | 0.088 | 0.44 (0.17–1.19) | 0.443 | 0.56 (0.21–1.49) | 0.244 | |
| T stage | T0 | reference | — | reference | — | reference | — | reference | — |
| T1 | 0.67 (0.52–0.87) | 0.003 | 0.79 (0.58–1.07) | 0.121 | 0.99 (0.76–1.29) | 0.934 | 1.13 (0.83–1.54) | 0.426 | |
| T2 | 0.85 (0.69–1.06) | 0.146 | 1.07 (0.83–1.39) | 0.588 | 1.27 (1.02–1.59) | 0.035 | 1.55 (1.19–2.01) | 0.001 | |
| T3 | 0.94 (0.75–1.18) | 0.617 | 1.28 (0.99–1.67) | 0.061 | 1.34 (1.06–1.70) | 0.014 | 1.77 (1.35–2.31) | P < 0.001 | |
| T4 | 1.28 (1.06–1.55) | 0.011 | 1.66 (1.32–2.09) | P < 0.001 | 1.62 (1.33–1.98) | P < 0.001 | 2.02 (1.60–2.57) | P < 0.001 | |
| Tx | 1.44 (1.19–1.75) | P < 0.001 | 1.69 (1.34–2.14) | P < 0.001 | 1.44 (1.18–1.75) | P < 0.001 | 1.68 (1.32–2.13) | P < 0.001 | |
| N stage | N0 | reference | — | reference | — | reference | — | reference | — |
| N1 | 0.93 (0.84-1.04) | 0.208 | 1.03 (0.92–1.17) | 0.592 | 0.91 (0.81–1.02) | 0.088 | 0.96 (0.85–1.09) | 0.503 | |
| N2 | 0.78 (0.66–0.91) | 0.001 | 0.85 (0.71–1.01) | 0.060 | 0.87 (0.73–1.03) | 0.095 | 0.90 (0.75–1.08) | 0.241 | |
| N3 | 0.92 (0.80–1.06) | 0.241 | 1.02 (0.88–1.19) | 0.757 | 1.00 (0.87-1.16) | 0.975 | 1.05 (0.90–1.24) | 0.5336 | |
| Nx | 1.34 (1.19–1.50) | P < 0.001 | 1.35 (1.18–1.54) | P < 0.001 | 1.07 (0.95–1.21) | 0.285 | 1.08 (0.94–1.24) | 0.293 | |
| Molecular subtype | Her2–/HoR + | reference | — | reference | — | reference | — | reference | — |
| Her2 + /HoR+ | 0.88 (0.76-1.02) | 0.085 | 0.86 (0.73–1.01) | 0.061 | 0.86 (0.74–1.00) | 0.035 | 0.81 (0.69–0.95) | 0.011 | |
| Her2+/HoR– | 1.17 (0.99–1.38) | 0.073 | 1.18 (0.99–1.42) | 0.066 | 1.08 (0.91–1.28) | 0.368 | 1.08 (0.89–1.29) | 0.439 | |
| Triple Negative | 2.29 (2.03–2.58) | P < 0.001 | 2.33 (2.05-0.65) | P < 0.001 | 2.26 (2.00–2.56) | P < 0.001 | 2.31 (2.02–2.64) | P < 0.001 | |
| Unknown | 1.78 (1.61–1.96) | P < 0.001 | 1.64 (1.47–1.83) | P < 0.001 | 1.53 (1.38–1.70) | P < 0.001 | 1.48 (1.32–1.66) | P < 0.001 | |
| Surgery | No | reference | — | reference | — | reference | — | reference | — |
| Yes | 0.49 (0.44-0.55) | P < 0.001 | 0.51 (0.45–0.57) | P < 0.001 | 0.61 (0.55–0.69) | P < 0.001 | 0.62 (0.55–0.70) | P < 0.001 | |
| Unknown | 1.21 (0.77–1.90) | 0.414 | 1.31 (0.81-2.11) | 0.270 | 1.54 (0.96–2.45) | 0.071 | 1.64 (1.00–2.69) | 0.051 | |
| Radiation | No | reference | — | reference | — | reference | — | reference | — |
| Yes | 0.72 (0.66–0.79) | P < 0.001 | 0.75 (0.68–0.83) | P < 0.001 | 0.79 (0.72–0.87) | P < 0.001 | 0.80 (0.72–0.89) | P < 0.001 | |
| Unknown | 0.65 (0.49-0.86) | 0.003 | 0.67 (0.49–0.91) | 0.010 | 0.77 (0.58–1.03) | 0.080 | 0.77 (0.56–1.06) | 0.109 | |
| Bone metastasis | No | reference | — | reference | — | reference | — | reference | — |
| Yes | 0.92 (0.85-1.00) | 0.040 | 0.97 (0.87–1.06) | 0.970 | 1.05 (0.96–1.15) | 0.267 | 1.11 (1.01–1.22) | 0.035 | |
| Lung metastasis | No | reference | — | reference | — | reference | — | reference | — |
| Yes | 1.47 (1.36-1.60) | P < 0.001 | 1.52 (1.39–1.67) | P < 0.001 | 1.22 (1.12–1.33) | P < 0.001 | 1.24 (1.13-1.36) | P < 0.001 | |
| Liver metastasis | No | reference | — | reference | — | reference | — | reference | — |
| Yes | 1.79 (1.64–1.94) | P < 0.001 | 1.90 (1.73–2.09) | P < 0.001 | 1.80 (1.65-1.97) | P < 0.001 | 1.90 (1.72–2.09) | P < 0.001 | |
| Brain metastasis | No | reference | — | reference | — | reference | — | reference | — |
| Yes | 1.81 (1.60–2.05) | P < 0.001 | 1.87 (1.64-2.14) | P < 0.001 | 1.74 (1.53–1.98) | P < 0.001 | 1.77 (1.54–2.04) | P < 0.001 | |
aHRs: hazard ratios; CI: confidence interval.